High Point-based Banner Pharmacaps, Inc. received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) last week for Amantadine Hydrochloride Soft Gel Capsules USP 100 mg, the generic equivalent of USL Pharma's Symmetrel.
Amantadine Hydrochloride Soft Gel Capsules are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules are also used in the treatment of parkinsonism and drug-induced extrapyramidal reactions.
Lannett Company, Inc., a manufacturer of generic pharmaceuticals, expects to begin marketing Amantadine Hydrochloride Soft Gel Capsules 100 mg in the next several months.
Banner Pharmacaps is a leader in the pharmaceutical industry in the development of soft gelatin dosage form technologies. The company is developing a proprietary portfolio of unique products and oral dosage forms that include the enhanced technologies of enteric and controlled-release softgels. For more information about Banner visit www.banpharm.com.